Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How do you decide when to stop immunosuppression in a patient with granulomatosis with polyangiitis who is on dialysis, has not yet recovered renal function, but has shown improvement in ANCA levels?
Related Questions
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
How would you treat idiopathic isolated renal TMA diagnosed on renal biopsy without evidence of MAHA?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
How would you tailor immunosuppression in an elderly patient presenting with primary FSGS?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
Do you wait until serum anti-GBM antibody titers are undetectable before hospital discharge in a patient with anti-GBM antibody disease with renal involvement who is receiving daily plasmapheresis, cyclophosphamide, and steroids?
